Related Experiment Video
Updated: Jun 29, 2025
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.3K
Five-Fraction High-Conformal Ultrahypofractionated Radiotherapy for Primary Tumors in Metastatic Breast Cancer
Jeongshim Lee1,2, Jee Hung Kim3, Mitchell Liu4
1Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Journal of Breast Cancer
|March 26, 2024
Summary
High-conformal ultrahypofractionated radiation therapy (RT) shows promising 2-year local control for metastatic breast cancer (MBC) primary tumors. This treatment was well-tolerated with minimal toxicity in a small patient cohort.
Area of Science:
- Oncology
- Radiation Oncology
- Breast Cancer Research
Background:
- Metastatic breast cancer (MBC) poses significant treatment challenges, particularly for primary tumors in patients not undergoing surgery.
- Optimizing radiation therapy (RT) techniques is crucial for improving local control and managing toxicity in this population.
Purpose of the Study:
- To evaluate the local control and toxicity of a 5-fraction, high-conformal ultrahypofractionated RT regimen for primary tumors in patients with MBC.
- To assess the efficacy of this novel RT approach in patients who did not receive planned surgical intervention.
Main Methods:
- Retrospective review of 27 MBC patients treated with 5-fraction, high-dose, intensity-modulated RT between 2017-2022.
- Median prescribed dose of 66.8 Gy (2-Gy equivalents, α/β=3.5) with a simultaneous integrated boost.
- Primary endpoint was local control, with toxicity and response rates also analyzed.
Main Results:
- The 2-year local control rate was 77% at a median follow-up of 18.3 months.
- Treatment was well-tolerated, with only 15% experiencing mild, self-resolving acute skin toxicity.
- An 82% infield response rate was observed, with a median time to objective response of 10.8 months.
Conclusions:
- 5-fraction, high-conformal ultrahypofractionated RT demonstrates promising local control and minimal toxicity for primary MBC tumors.
- Further research is needed to determine the optimal dose and role of this RT modality in MBC management.
